DBV Technologies S.A.
$2.84▼ 1.11%($-0.03)
TickerSpark Score
46/100
▌ Weak
60
Valuation
20
Profitability
35
Growth
84
Health
30
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DBV.PA research report →
52-Week Range46% of range
Low
$1.45
Current
$2.84
High
$4.50
Company Overviewwww.dbv-technologies.com
About the company
DBV Technologies S. A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products.
- CEO
- Daniel Tassé
- IPO
- 2012
- Employees
- 106
- HQ
- Montrouge, FR
Price Chart
+78.62% · this period
Valuation
- Market Cap
- $480.57M
- P/E
- -3.33
- P/S
- 0.00
- P/B
- 6.65
- EV/EBITDA
- -2.04
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -130.06%
- ROIC
- -74.64%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-152,938,019 · -34.25%
- EPS
- $-1.09 · 6.84%
- Op Income
- $-158,917,241
- FCF YoY
- -18.59%
Performance & Tape
- 52W High
- $4.50
- 52W Low
- $1.45
- 50D MA
- $3.25
- 200D MA
- $3.10
- Beta
- -0.22
- Avg Volume
- 955.43K
Get TickerSpark's AI analysis on DBV.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · DBV.PA
Our DBV.PA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on DBV.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DBV.PA report →Internal Compare
Similar companies
Peers in the same neighborhood.